Press release
High-Grade Glioma Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by Delveinsight | Basilea Pharma, Erimos Pharma, Adastra Pharma, Chimerix, BioMimetix, Oblato, Inc.
The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"High-Grade Glioma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the High-Grade Glioma Market.
Some of the key takeaways from the High-Grade Glioma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel High-Grade Glioma treatment therapies with a considerable amount of success over the years.
*
High-Grade Glioma companies working in the treatment market are Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others, are developing therapies for the High-Grade Glioma treatment
*
Emerging High-Grade Glioma therapies in the different phases of clinical trials are- ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others are expected to have a significant impact on the High-Grade Glioma market in the coming years.
*
In April 2025, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company advancing multimodal biological immunotherapies for cancer treatment, has announced the publication of a manuscript detailing the findings of a Phase 1b clinical trial. The study assessed the safety and tolerability of combining CAN-2409 with a prodrug (valacyclovir) and nivolumab, alongside standard treatments-neurosurgery, radiotherapy, and temozolomide-in patients newly diagnosed with high-grade glioma.
*
In March 2025, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotech company advancing next-generation targeted antitumor virotherapies, in collaboration with City of Hope-one of the leading U.S. cancer research and treatment institutions-has announced encouraging progress from a Phase 1 clinical trial. The study evaluates Calidi's investigational agent CLD-101, a neural stem cell-based oncolytic virotherapy delivered intracerebrally. This marks the first trial assessing the safety and therapeutic potential of a multiple-dose regimen of CLD-101 in patients with recurrent high-grade glioma, one of the most aggressive and lethal brain cancers.
*
In March 2025, Anova Enterprises, Inc. (Anova), a technology-driven CRO focused on expediting innovative treatments, has announced the enrollment of the first two patients in the Phase 1/2a clinical trial of DB107 for brain tumors. This multicenter, open-label study aims to evaluate whether DB107, when combined with the standard of care (SOC), offers clinical benefits to patients with newly diagnosed high-grade gliomas (HGG) compared to historical outcomes.
*
In August 2024, Predictive diagnostics company Kiyatec revealed data demonstrating that its 3D Predict Glioma test enhances survival outcomes for patients with high-grade glioma (HGG) by accurately forecasting their response to chemotherapy. Published in Scientific Reports, the findings show that test responders experienced a median progression-free survival extension of 5.8 months and an overall survival increase of 7.6 months compared to non-responders. The study (NCT03561207) included 102 patients newly diagnosed with HGG, a cancer known for its poor prognosis.
*
In May 2024, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110. This next-generation oncolytic viral immunotherapy is intended for treating recurrent high-grade glioma (rHGG). Glioblastoma (GBM), the most prevalent and aggressive type of high-grade glioma, remains a significant therapeutic challenge.
*
In April 2024, Denovo Biopharma LLC (Denovo), a leader in utilizing precision medicine for developing innovative treatments, has announced that the California Institute for Regenerative Medicine (CIRM) has granted $11.8 million for the continued advancement of DB107. This is Denovo's DGM7 Trademark biomarker-guided late-stage gene therapy aimed at high-grade glioma (HGG), including glioblastoma (GBM), a type of malignant brain cancer. The grant has been awarded to Dr. Noriyuki Kasahara, MD, PhD, at the University of California San Francisco (UCSF), along with a team of researchers from California universities, to conduct a Phase 1/2 clinical trial evaluating DB107 in patients newly diagnosed with HGG.
High-Grade Glioma Overview
High-grade glioma (HGG) refers to a group of aggressive brain tumors that originate from glial cells, which provide support and protection for neurons. These tumors are classified as high-grade due to their rapid growth and tendency to invade surrounding brain tissue, making them difficult to treat. The most common type of HGG is glioblastoma multiforme (GBM), characterized by its heterogeneous cellular makeup and resistance to therapy. Symptoms of HGG can include headaches, seizures, cognitive changes, and neurological deficits, depending on the tumor's location in the brain. Treatment typically involves a combination of surgery, radiation therapy, and chemotherapy, but the prognosis remains poor, with limited survival rates.
Get a Free Sample PDF Report to know more about High-Grade Glioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight [https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging High-Grade Glioma Drugs Under Different Phases of Clinical Development Include:
*
ONC201: Chimerix
*
BMX-001: BioMimetix
*
OKN-007: Oblato, Inc.
*
Lisavanbulin: Basilea Pharmaceutica
*
Terameprocol: Erimos Pharmaceuticals
*
Zotiraciclib: Adastra Pharmaceuticals/S*Bio
*
PTC596: PTC Therapeutics
*
OS2966: OncoSynergy
*
CAN 3110: Candel Therap
*
DSP 0390: Sumitomo Pharma Oncology, Inc.
*
Terameprocol: Erimos Pharmaceuticals
*
Lenvatinib: Eisai Inc.
*
PVSRIPO: Istari Oncology, Inc.
*
BMX-001: BioMimetix Pharma
High-Grade Glioma Route of Administration
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Infusion
*
Intradermal
*
Intramuscular
*
Intranasal
*
Intravenous
*
Oral
*
Parenteral
*
Subcutaneous
*
Molecule Type
High-Grade Glioma Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types, such as
*
Gene therapies
*
Small molecule
*
Vaccines
*
Polymers
*
Peptides
*
Monoclonal antibodies
*
Product Type
High-Grade Glioma Pipeline Therapeutics Assessment
*
High-Grade Glioma Assessment by Product Type
*
High-Grade Glioma By Stage and Product Type
*
High-Grade Glioma Assessment by Route of Administration
*
High-Grade Glioma By Stage and Route of Administration
*
High-Grade Glioma Assessment by Molecule Type
*
High-Grade Glioma by Stage and Molecule Type
DelveInsight's High-Grade Glioma Report covers around 150+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further High-Grade Glioma product details are provided in the report. Download the High-Grade Glioma pipeline report to learn more about the emerging High-Grade Glioma therapies [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the High-Grade Glioma Therapeutics Market include:
Key companies developing therapies for High-Grade Glioma are - Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.
High-Grade Glioma Pipeline Analysis:
The High-Grade Glioma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.
*
High-Grade Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about High-Grade Glioma drugs and therapies [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
High-Grade Glioma Pipeline Market Drivers
*
Increasing the prevalence of High Grade Glioma, increase in the accessibility to more options for the treatment and diagnosis of a high-grade tumor are some of the important factors that are fueling the High-Grade Glioma Market.
High-Grade Glioma Pipeline Market Barriers
*
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the High-Grade Glioma Market growth.
Scope of High-Grade Glioma Pipeline Drug Insight
*
Coverage: Global
*
Key High-Grade Glioma Companies: Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others
*
Key High-Grade Glioma Therapies: ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others
*
High-Grade Glioma Therapeutic Assessment: High-Grade Glioma current marketed and High-Grade Glioma emerging therapies
*
High-Grade Glioma Market Dynamics: High-Grade Glioma market drivers and High-Grade Glioma market barriers
Request for Sample PDF Report for High-Grade Glioma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. High-Grade Glioma Report Introduction
2. High-Grade Glioma Executive Summary
3. High-Grade Glioma Overview
4. High-Grade Glioma- Analytical Perspective In-depth Commercial Assessment
5. High-Grade Glioma Pipeline Therapeutics
6. High-Grade Glioma Late Stage Products (Phase II/III)
7. High-Grade Glioma Mid Stage Products (Phase II)
8. High-Grade Glioma Early Stage Products (Phase I)
9. High-Grade Glioma Preclinical Stage Products
10. High-Grade Glioma Therapeutics Assessment
11. High-Grade Glioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. High-Grade Glioma Key Companies
14. High-Grade Glioma Key Products
15. High-Grade Glioma Unmet Needs
16 . High-Grade Glioma Market Drivers and Barriers
17. High-Grade Glioma Future Perspectives and Conclusion
18. High-Grade Glioma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=highgrade-glioma-pipeline-2025-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-basilea-pharma-erimos-pharma-adastra-pharma-chimerix-biomimetix-oblato-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High-Grade Glioma Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by Delveinsight | Basilea Pharma, Erimos Pharma, Adastra Pharma, Chimerix, BioMimetix, Oblato, Inc. here
News-ID: 3997846 • Views: …
More Releases from ABNewswire
Scoliosis Therapeutics Market Poised for Substantial Growth by 2032, Driven by a …
The scoliosis treatment market is poised for substantial growth, fueled by increasing disease awareness, technological advancements, and the development of innovative therapeutic interventions by key scoliosis companies, including Medicrea, Ellipse Technologies Inc, Apifix, Spinologics Inc, EOS imaging Inc, GE Healthcare, K2M Inc, Zimmer Biomet, Exponent Inc, Medtronic, NuVasive, and Bioventus LLC, among others.
DelveInsight's "Scoliosis Market Insight, Epidemiology and Market Forecast - 2032 [https://www.delveinsight.com/report-store/scoliosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the…
Rotator Cuff Injuries Market Poised for Significant Growth by 2032, Driven by In …
The rotator cuff injuries treatment market is expected to witness substantial growth, primarily fueled by an increasing prevalence, an aging population, advancements in minimally invasive surgical techniques, and the emergence of novel biologic therapies. Key rotator cuff repair companies, including Ortho Regenerative Technologies, Angiocrine Bioscience, Smith & Nephew, Arcuro Medical, and Atreon Orthopedics, are at the forefront of innovation, addressing the significant unmet needs.
DelveInsight's "Rotator Cuff Injuries Market Insights, Epidemiology,…
Herpes Simplex Market to Expand Significantly by 203, States DelveInsight Report …
The Key Herpes Simplex Companies in the market include - Labo'Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others.
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain,…
Lumbar Spondylolisthesis Treatment Market Projected to Witness Significant Growt …
The lumbar spondylolisthesis market is expected to demonstrate a promising CAGR by 2032. This growth trajectory is primarily fueled by increasing prevalence across aging populations, enhanced diagnostic capabilities, and a robust pipeline of novel therapeutic approaches by key spondylolisthesis companies including Abbott, Medtronic, Stryker, Johnson & Johnson, Zimmer Biomet, Globus Medical, NuVasive, and Orthofix leading innovation in both conservative management and surgical interventions.
DelveInsight's "Lumbar Spondylolisthesis - Market Insight, Epidemiology And…
More Releases for Glioma
Growth Dynamics of Adult Malignant Glioma Therapeutics Market
Increasing Prevalence of malignant glioma is a key factor driving the adult malignant glioma therapeutics market, says Fortune Business Insights in a report, titled "Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2026." The global adult malignant glioma therapeutics market size was valued at USD 1,459.1 Million…
Malignant Glioma Market Trends & Projection to 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons…
Optic Nerve Glioma Market Global Analysis & Forecast to 2023
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are…
Malignant Glioma Market to Significant Growth Foreseen by 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons…
Malignant Glioma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Malignant Glioma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Malignant Glioma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Malignant Glioma by development stage, therapy type, route of…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
